The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating Activity
Abstract
The metabolic syndrome is a common precursor of cardiovascular disease and type 2 diabetes that is characterized by the clustering of insulin resistance, dyslipidemia, and increased blood pressure. In humans, mutations in the peroxisome proliferator–activated receptor-γ (PPARγ) have been reported to cause the full-blown metabolic syndrome, and drugs that activate PPARγ have proven to be effective agents for the prevention and treatment of insulin resistance and type 2 diabetes. Here we report that telmisartan, a structurally unique angiotensin II receptor antagonist used for the treatment of hypertension, can function as a partial agonist of PPARγ; influence the expression of PPARγ target genes involved in carbohydrate and lipid metabolism; and reduce glucose, insulin, and triglyceride levels in rats fed a high-fat, high-carbohydrate diet. None of the other commercially available angiotensin II receptor antagonists appeared to activate PPARγ when tested at concentrations typically achieved in plasma with conventional oral dosing. In contrast to ordinary antihypertensive and antidiabetic agents, molecules that can simultaneously block the angiotensin II receptor and activate PPARγ have the potential to treat both hemodynamic and biochemical features of the metabolic syndrome and could provide unique opportunities for the prevention and treatment of diabetes and cardiovascular disease in high-risk populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883 · cited 1×
“These findings (1) demonstrate that at least one of the ARBs currently in clinical use has the capacity to activate PPAR and (2) suggest a number of interesting opportunities for developing improved therapeutic approaches to the metabolic syndrome as well as type 2 diabetes and other clinical disorders that might be i…”
BackgroundThe ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Park, Y.-W., Zhu, S., Palaniappan, L., Heshka, S., Carnethon, M. R., & Heymsfield, S. B. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.4.427 · Cited by 2,074
Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 2,014
Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ
Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., Kurokawa, R., Rosenfeld, M. G., Willson, T. M., Glass, C. K., & Milburn, M. V. (1998) · Nature · doi:10.1038/25931 · Cited by 1,958
Transcriptional regulation of adipogenesis
Rosen, E. D., Walkey, C. J., Puigserver, P., & Spiegelman, B. M. (2000) · Genes & Development · doi:10.1101/gad.14.11.1293 · Cited by 1,898
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
Granger, C. B., McMurray, J. J., Yusuf, S., Held, P., Michelson, E. L., Olofsson, B., Östergren, J., Pfeffer, M. A., & Swedberg, K. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14284-5 · Cited by 1,686
Reaven, G. M., Lithell, H., & Landsberg, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602083340607 · Cited by 1,435
Lithell, H., Hansson, L., Skoog, I., Elmfeldt, D., Hofman, A., Olofsson, B., Trenkwalder, P., & Zanchetti, A. (2003) · Journal of Hypertension · doi:10.1097/00004872-200305000-00011 · Cited by 1,409
Processing of gene expression data generated by quantitative real-time RT-PCR.
Muller, P. Y., Janovjak, H., Miserez, A. R., & Dobbie, Z. (2002) · PubMed · Cited by 1,394
PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth
Rosen, E. D., & Spiegelman, B. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100034200 · Cited by 1,175
Wing, L. M. H., Reid, C. M., Ryan, P., Beilin, L. J., Brown, M. A., Jennings, G. L. R., Johnston, C. I., McNeil, J. J., Macdonald, G. J., Marley, J. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021716 · Cited by 1,130
McMurray, J. J. V., Östergren, J., Swedberg, K. B., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer (2003) · The Lancet · Cited by 1,043
Ram�rez-Zacar�as, J. L., Castro-Mu�ozledo, F., & Kuri-Harcuch, W. (1992) · Histochemistry · doi:10.1007/bf00316069 · Cited by 1,008
Laaksonen, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf145 · Cited by 916
Angiotensin II receptor antagonists
Burnier, M., & Brunner, H. (2000) · The Lancet · doi:10.1016/s0140-6736(99)10365-9 · Cited by 707
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Ramipril and the Development of Diabetes
Yusuf, S. (2001) · JAMA · doi:10.1001/jama.286.15.1882 · Cited by 541
Insulin-like growth factor-I is an essential regulator of the differentiation of 3T3-L1 adipocytes.
Smith, P. J., Wise, L. S., Berkowitz, R., Wan, C., & Rubin, C. S. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)76555-7 · Cited by 517
Failure of adipocyte differentiation causes type II diabetes mellitus?
Danforth, E. (2000) · Nature Genetics · doi:10.1038/79111 · Cited by 487
Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
Taal, M. W., & Brenner, B. M. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00031.x · Cited by 439
PPARγ AND G LUCOSE H OMEOSTASIS
Picard, F., & Auwerx, J. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.010402.102808 · Cited by 411
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
Lindholm, L. H., Ibsen, H., Borch-Johnsen, K., Olsen, M. H., Wachtell, K., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., et al. (2002) · Journal of Hypertension · doi:10.1097/00004872-200209000-00035 · Cited by 392
Abu-Elheiga, L., Oh, W., Kordari, P., & Wakil, S. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1733877100 · Cited by 389
Peroxisome Proliferator-Activated Receptors: Vascular and Cardiac Effects in Hypertension
Schiffrin, E. L., Amiri, F., Benkirane, K., Iglarz, M., & Diep, Q. N. (2003) · Hypertension · doi:10.1161/01.hyp.0000084370.74777.b6 · Cited by 369
Janke, J., Engeli, S., Gorzelniak, K., Luft, F. C., & Sharma, A. M. (2002) · Diabetes · doi:10.2337/diabetes.51.6.1699 · Cited by 322
Berger, J. P., Petro, A. E., Macnaul, K. L., Kelly, L. J., Zhang, B. B., Richards, K., Elbrecht, A., Johnson, B. A., Zhou, G., Doebber, T. W., et al. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0217 · Cited by 321
A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation
Oberfield, J. L., Collins, J. L., Holmes, C. P., Goreham, D. M., Cooper, J. P., Cobb, J. E., Lenhard, J. M., Hull-Ryde, E. A., Mohr, C. P., Blanchard, S. G., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6102 · Cited by 316
Lindholm, L. H., Persson, M., Alaupovic, P., Carlberg, B., Svensson, A., & Samuelsson, O. G. (2003) · PubMed · doi:10.1097/01.hjh.0000084723.53355.76 · Cited by 308
Selective Angiotensin II Receptor Antagonism Reduces Insulin Resistance in Obese Zucker Rats
Henriksen, E. J., Jacob, S., Kinnick, T. R., Teachey, M. K., & Krekler, M. (2001) · Hypertension · doi:10.1161/hy1101.092970 · Cited by 293
Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells
Sharma, A. M., Janke, J., Gorzelniak, K., Engeli, S., & Luft, F. C. (2002) · Hypertension · doi:10.1161/01.hyp.0000036448.44066.53 · Cited by 283
A Unique PPARγ Ligand with Potent Insulin-Sensitizing yet Weak Adipogenic Activity
Rocchi, S., Picard, F., Vamecq, J., Gelman, L., Potier, N., Zeyer, D., Dubuquoy, L., Bac, P., Champy, M.-F., Plunket, K. D., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00353-7 · Cited by 272
PPARadigms and PPARadoxes: expanding roles for PPARγ in the control of lipid metabolism
Walczak, R., & Tontonoz, P. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30159-0 · Cited by 270
Lindholm, L. H., Persson, M., Alaupovic, P., Carlberg, B., Svensson, A., & Samuelsson, O. (2003) · Journal of Hypertension · doi:10.1097/00004872-200308000-00022 · Cited by 266
Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.
Buchanan, T. A., Meehan, W. P., Jeng, Y. Y., Yang, D., Chan, T. M., Nadler, J. L., Scott, S., Rude, R. K., & Hsueh, W. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118041 · Cited by 238
Grassi, G., Seravalle, G., Dell'Oro, R., Trevano, F. Q., Bombelli, M., Scopelliti, F., Facchini, A., & Mancia, G. (2003) · Journal of Hypertension · doi:10.1097/00004872-200309000-00027 · Cited by 225
Camp, H. S., Li, O., Wise, S. C., Hong, Y. H., Frankowski, C. L., Shen, X., Vanbogelen, R., & Leff, T. (2000) · Diabetes · doi:10.2337/diabetes.49.4.539 · Cited by 224
Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes
Delea, T. E., Edelsberg, J. S., Hagiwara, M., Oster, G., & Phillips, L. S. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.2983 · Cited by 216
Stangier, J., Su, C., & Roth, W. (2000) · Journal of International Medical Research · doi:10.1177/147323000002800401 · Cited by 210
Sunder, M., Chang, A. R., & Henry, R. R. (2003) · Endocrine Practice · doi:10.4158/ep.9.5.406 · Cited by 209
Reginato, M. J., Bailey, S. T., Krakow, S. L., Minami, C., Ishii, S., Tanaka, H., & Lazar, M. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32679 · Cited by 185
Gerhold, D. L., Liu, F., Jiang, G., Li, Z., Xu, J., Lu, M., Sachs, J. R., Bagchi, A., Fridman, A., Holder, D. J., et al. (2002) · Endocrinology · doi:10.1210/endo.143.6.8842 · Cited by 183
Thiazolidinediones Block Fatty Acid Release by Inducing Glyceroneogenesis in Fat Cells
Tordjman, J., Chauvet, G., Quette, J., Beale, E. G., Forest, C., & Antoine, B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m206999200 · Cited by 178
A molecular mechanics/grid method for evaluation of ligand–receptor interactions
Luty, B. A., Wasserman, Z. R., Stouten, P. F. W., Hodge, C. N., Zacharias, M., & McCammon, J. A. (1995) · Journal of Computational Chemistry · doi:10.1002/jcc.540160409 · Cited by 165
ACE Inhibitor Improves Insulin Resistance in Diabetic Mouse Via Bradykinin and NO
Shiuchi, T., Cui, T., Wu, L., Nakagami, H., Takeda-Matsubara, Y., Iwai, M., & Horiuchi, M. (2002) · Hypertension · doi:10.1161/01.hyp.0000028979.98877.0c · Cited by 159
Hsueh, W. A., & Law, R. E. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00610-6 · Cited by 148
Smith, U., Gogg, S., JOHANSSON, A., Olausson, T., Sopasakis, V. R., & SVALSTEDT, B. (2001) · The FASEB Journal · doi:10.1096/fj.00-0020com · Cited by 131
Auwerx, J. H. (2002) · Cited by 127
Tomiyama, H., Kushiro, T., Abeta, H., Ishii, T., Takahashi, A., Furukawa, L. N. S., Asagami, T., Hino, T., Saito, F., & Otsuka, Y. (1994) · Hypertension · doi:10.1161/01.hyp.23.4.450 · Cited by 118
Insulin-Sensitizing Effects of Telmisartan
Pershadsingh, H. A., & Kurtz, T. W. (2004) · Diabetes Care · doi:10.2337/diacare.27.4.1015 · Cited by 92
Self-citationVasodilatory edema: a common side effect of antihypertensive therapy
Messerli, F. H. (2001) · American Journal of Hypertension · doi:10.1016/s0895-7061(01)02178-1 · Cited by 87
Novel Genes Regulated by the Insulin Sensitizer Rosiglitazone During Adipocyte Differentiation
Albrektsen, T., Frederiksen, K. S., Holmes, W. E., Boel, E., Taylor, K. J., & Fleckner, J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1042 · Cited by 76
Pharmacogenetic Evidence That Cd36Is a Key Determinant of the Metabolic Effects of Pioglitazone
Qi, N., Kazdová, L., Zídek, V., Landa, V., Křen, V., Pershadsingh, H. A., Lezin, E. S., Abumrad, N. A., Pravenec, M., & Kurtz, T. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206655200 · Cited by 65
Self-citationSabnis, Y. A., Desai, P. V., Rosenthal, P. J., & Avery, M. A. (2003) · Protein Science · doi:10.1110/ps.0228103 · Cited by 57
Self-citationDirect Vasodepressor Effects of Pioglitazone in Spontaneously Hypertensive Rats
Verma, S., Bhanot, S., Arikawa, E., Yao, L., & McNeill, J. H. (1998) · Pharmacology · doi:10.1159/000028177 · Cited by 43
Attenuation of Hypertension by Insulin-Sensitizing Agents
Kotchen, T. A. (1996) · Hypertension · doi:10.1161/01.hyp.28.2.219 · Cited by 38
The Role of the Angiotensin System in Cardiac Glucose Homeostasis: Therapeutic Implications
Bernobich, E., Angelis, L. D., Lerín, C., & Bellini, G. (2002) · Drugs · doi:10.2165/00003495-200262090-00002 · Cited by 36
Chewing the Fat--ACC and Energy Balance
Ruderman, N. B., & Flier, J. S. (2001) · Science · doi:10.1126/science.1060277 · Cited by 35
(2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)01235-9 · Cited by 5
Alberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
Cited by
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
Mehta, P. K., & Griendling, K. K. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00287.2006 · Cited by 1,924
Luo, Y., Zhao, X., Zhou, J., Yang, J., Zhang, Y., Kuang, W., Peng, J., Chen, L., & Zeng, J. (2017) · Nature Communications · doi:10.1038/s41467-017-00680-8 · Cited by 916
Grundy, S. M. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.10.004 · Cited by 882
Renin-angiotensin system and cardiovascular risk
Schmieder, R. E., Hilgers, K. F., Schlaich, M. P., & Schmidt, B. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60242-6 · Cited by 663
Bays, H. E., González-Campoy, J. M., Bray, G. A., Kitabchi, A. E., Bergman, D. A., Schorr, A. B., Rodbard, H. W., & Henry, R. R. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.3.343 · Cited by 530
Metadata
- Authors
- Benson, S. C., Pershadsingh, H. A., Ho, C. I., Chittiboyina, A., Desai, P., Pravenec, M., Qi, N., Wang, J., Avery, M. A., & Kurtz, T. W.
- Venue
- Hypertension
- Published
- 2004-05
- Volume
- 43
- Issue
- 5
- Pages
- 993-1002
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2129697991
- Cited by
- 1,073
- References
- 69
- FWCI
- 23.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.